<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02598089</url>
  </required_header>
  <id_info>
    <org_study_id>IVACFLU-S-01</org_study_id>
    <nct_id>NCT02598089</nct_id>
    <nct_alias>NCT02809209</nct_alias>
  </id_info>
  <brief_title>Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S)</brief_title>
  <acronym>IVACFLU-S</acronym>
  <official_title>A Phase 1 Double Blinded, Randomized, Placebo-Controlled Study In Healthy Adult Volunteers In Vietnam To Examine The Safety And Immunogenicity Of A Seasonal Trivalent Inactivated Split Virion Influenza Vaccine (IVACFLU-S) Produced By IVAC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Vaccines and Medical Biologicals, Vietnam</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Hygiene and Epidemiology, Vietnam</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Vaccines and Medical Biologicals, Vietnam</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, double-blind, randomized, placebo-controlled trial with two groups of
      subjects to receive seasonal trivalent inactivated split virion influenza vaccine (A/H1N1;
      A/H3N2 and B strains) or placebo (phosphate buffered saline). A total of 60 healthy male and
      female adults 18 through 45 years of age will be randomized to receive vaccine (30) or
      placebo (30).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1, single center, double blinded, randomized, placebo-controlled study. Sixty
      (60) healthy male and female adults, 18 to 45 years of age, will be enrolled into the trial.
      Subjects will be randomized 1:1 to one of two treatment allocations: 30 to vaccine, 30 to
      placebo. The study will utilize a &quot;randomized block design&quot; to assure a balance of 1:1
      vaccine and placebo when all subjects are enrolled. The study will be double blinded, meaning
      the study subjects, investigators, and the sponsor will be unaware of the treatment allocated
      to each subject until the clinical trial database is declared final and locked. The study
      should take about 5 months to complete, with each subject involved for 3 months from the day
      of injection. The justification for the 3 month follow up, rather than 6 month follow up is
      that this is an inactivated vaccine that follows very standard manufacturing practices with
      standard antigens. The safety of inactivated influenza vaccines is well-established. Adding
      length to the follow up results in delays in future testing of the vaccine for licensure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Immediate Adverse Events</measure>
    <time_frame>30-minute post-vaccination period.</time_frame>
    <description>Any adverse event occurring within the 30 minute post vaccination period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and Percentage of Participants Reporting Solicited Local Reactogenicity</measure>
    <time_frame>7-day period (Days 1-7) post-vaccination.</time_frame>
    <description>Number of subjects reporting solicited local reactions (redness, swelling, pain, hardness, and tenderness) at the injection site post-vaccination with study vaccine or placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity</measure>
    <time_frame>7-day period (Days 1-7) post-vaccination</time_frame>
    <description>Number of subjects reporting solicted systemic reactions (fever, fatigue/malaise, muscle aches, joint aches, chills, nausea, vomiting, and headache) post-vaccination with study vaccine or placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and Percentage of Participants With Unsolicited Adverse Events</measure>
    <time_frame>Within 21 days post-vaccination</time_frame>
    <description>Unsolicited AEs were any AEs that occurred any time after the vaccine/placebo was administered (temporally related to investigational product), whether or not deemed &quot;related&quot; to the product, and are not solicited (specifically asked of the subject). Unsolicited AEs were to be observed by the study center personnel while the subject was at the study center for a study visit or reported by the subject at any time. Any sign or symptom that would normally be considered a &quot;solicited AE&quot; (for example, fever, nausea, injection site pain) starting after 7 days post-vaccination were to be recorded as an &quot;unsolicited AE. In this study, laboratory results were considered AEs when (1) the result was judged to be clinically significant by the Principal Investigator, regardless of grade; or (2) the result is Grade 2 or higher.
Note: all unsolicited AEs were mild in intensity. Please see Adverse Events section of this report for detailed information of AEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and Percentage of Participants With Serious Adverse Events (SAEs)</measure>
    <time_frame>Over the entire study period (Day 91)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Subjects With Seroconversion Against Each of the 3 Antigens</measure>
    <time_frame>Day 22</time_frame>
    <description>Seroconversion is defined as a serum HAI titer meeting the following criteria:
pre-vaccination titer &lt;1:10 and a post-vaccination titer ≥ 1:40 or
pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination measured on Day 22.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Seroprotected Subjects Against 3 Strains of Influenza Vaccine</measure>
    <time_frame>Day 1 and Day 22 post vaccination</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject who had a serum Hemagluttination Inhibition (HAI) titer &gt;/= 1:40. The 3 influenza strains assessed were B, H1, and H3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Serum Hemaggluntination Inhibition (HAI) Antibodies for Each Antigen</measure>
    <time_frame>Pre- (Day 1) and post-vaccination (Day 22)</time_frame>
    <description>Geometric mean titers (GMTs) of Serum Hemaggluntination Inhibition (HAI) antibodies pre- (Day 1) and post-vaccination (Day 22) for each of the 3 antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rises (GMFRs) of Serum Hemaggluntination Inhibition (HAI) Antibodies</measure>
    <time_frame>Day 22/Day1</time_frame>
    <description>Geometric mean fold rises (GMFRs) of serum hemaggluntination inhibition (HAI) antibodies post-vaccination/pre-vaccination for each of the 3 antigens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Neutralization Titers of Neutralizing Antibodies (MNT) Pre- (Day 1) and Post-Vaccination (Day 22) for Each of the 3 Antigens</measure>
    <time_frame>Pre- (Day 1) and Post-vaccination (Day 22)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Fold Rises (GMFRs) of Neutralizing Antibodies (MNT) Post-vaccination/Pre-vaccination for Each of the 3 Antigens</measure>
    <time_frame>Pre- (Day 1) and Post-vaccination (Day 22)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Influenza, Human</condition>
  <arm_group>
    <arm_group_label>Trivalent Seasonal Influenza Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mL of seasonal trivalent influenza vaccine with 15 mcg of HA of each of 3 strains:
NYMC BX-51B reassortant of B/Massachusetts/2/2012
NYMC X‐179A reassortant of A/California/7/2009 (H1N1)
NYMC X-223A reassortant of H3/A/Texas/50/2012 (H3N2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This is the placebo comparator: 0.5 mL of Phosphate Buffered Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent Seasonal Influenza Vaccine</intervention_name>
    <arm_group_label>Trivalent Seasonal Influenza Vaccine</arm_group_label>
    <other_name>IVACFLU-S</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.5 mL of phosphate buffered saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female adult 18 through 45 years of age at the enrollment visit.

          -  Literate (by self-report) and willing to provide written informed consent.

          -  Healthy, as established by the medical history, physical examination, and screening
             laboratory evaluations.

          -  Capable and willing to complete Diary Cards and willing to return for all follow-up
             visits.

          -  For females, willing to utilize reliable birth control measures (e.g., intrauterine
             device, hormonal contraception, condoms) through the Day 22 visit.

        Exclusion Criteria:

          -  Participation in another clinical trial involving any therapy within the previous
             three months or planned enrollment in such a trial during the period of this study.

          -  Receipt of any non-study vaccine within 4 weeks prior to enrollment or refusal to
             postpone receipt of such vaccines until after the Day 22 visit.

          -  Current or recent (within 2 weeks of enrollment) acute illness with or without fever.

          -  Receipt of immune globulin or other blood products within 3 months prior to study
             enrollment or planned receipt of such products prior to the Day 22 visit.

          -  Chronic administration (defined as more than 14 consecutively-prescribed days) of
             immunosuppressants or other immune-modulating therapy within six months prior to study
             enrollment. (For corticosteroids, this means prednisone or equivalent, 0.5 mg per kg
             per day; topical steroids are allowed.)

          -  History of asthma.

          -  Hypersensitivity after previous administration of any vaccine.

          -  Suspected or known hypersensitivity to any of the study vaccine components, including
             chicken or egg protein, antibiotics, and rubber (from the vaccine vial stoppers).

          -  Acute or chronic clinically significant pulmonary, cardiovascular, hepatobiliary,
             metabolic, neurologic, psychiatric or renal functional abnormality, as determined by
             medical history, physical examination or clinical laboratory screening tests, which in
             the opinion of the investigator, might interfere with the study objectives.

          -  History of any blood or solid organ cancer.

          -  History of thrombocytopenic purpura or known bleeding disorder.

          -  History of seizures.

          -  Known or suspected immunosuppressed or immunodeficient condition of any kind.

          -  Confirmed hepatitis B virus (HBV) or hepatitis C virus (HCV) infection

          -  Known human immunodeficiency virus (HIV) infection (self-report).

          -  Known active tuberculosis or symptoms of active tuberculosis, regardless of cause
             (self-report).

          -  History of chronic alcohol abuse and/or illegal drug use.

          -  Pregnancy or lactation. (A negative pregnancy test will be required before
             administration of study product for all women of childbearing potential.)

          -  History of Guillain-Barré Syndrome

          -  Any condition that, in the opinion of the investigator, would increase the health risk
             to the subject if he/she participates in the study or would interfere with the
             evaluation of the study objectives.

        Note: Minor out-of-range laboratory values no greater than Grade 1 will not be considered
        to be exclusionary at screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dang D. Anh, Ph. D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Hygiene and Epidemiology, Vietnam</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hung Ha District Health Center</name>
      <address>
        <city>Thai Binh</city>
        <state>Thai Binh Province</state>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/27567493</url>
    <description>Article published in the journal Vaccine</description>
  </link>
  <results_reference>
    <citation>Anh DD, Thiem VD, Anh NTH, Huong VM, Nga NT, Thang TC, Thai DH, Chien VC, Holt R, Wahid R, Flores J, Berlanda Scorza F, Taylor DN. Randomized safety and immunogenicity trial of a seasonal trivalent inactivated split virion influenza vaccine (IVACFLU-S) in healthy young Vietnamese adults. Vaccine. 2016 Oct 26;34(45):5457-5462. doi: 10.1016/j.vaccine.2016.08.052. Epub 2016 Aug 24.</citation>
    <PMID>27567493</PMID>
  </results_reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>November 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2015</study_first_posted>
  <results_first_submitted>August 14, 2018</results_first_submitted>
  <results_first_submitted_qc>August 14, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 28, 2019</results_first_posted>
  <last_update_submitted>January 28, 2019</last_update_submitted>
  <last_update_submitted_qc>January 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Seasonal Influenza</keyword>
  <keyword>Trivalent Vaccine</keyword>
  <keyword>Inactivated Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Sixty four (64) subjects were consented and 4 were not randomized, leaving 60 subjects for the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Trivalent Seasonal Influenza Vaccine</title>
          <description>0.5 mL of seasonal trivalent influenza vaccine with 15 mcg of HA of each of 3 strains: B, H1N1 &amp; H3N2</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>0.5 mL of Phosphate Buffered Saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Trivalent Seasonal Influenza Vaccine</title>
          <description>0.5 mL of seasonal trivalent influenza vaccine with 15 mcg of HA of each of 3 strains: B, H1N1, &amp; H3N2</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>0.5 mL of Phosphate Buffered Saline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.7" lower_limit="27" upper_limit="45"/>
                    <measurement group_id="B2" value="37.8" lower_limit="21" upper_limit="45"/>
                    <measurement group_id="B3" value="37.8" lower_limit="21" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Kinh</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Vietnam</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Immediate Adverse Events</title>
        <description>Any adverse event occurring within the 30 minute post vaccination period.</description>
        <time_frame>30-minute post-vaccination period.</time_frame>
        <population>The analysis was conducted for subjects who were randomized and received a study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Group</title>
            <description>0.5 mL of influenza vaccine split, inactivated with 15 mcg of HA of each of 3 strains: B, H1N1, &amp; H3N2</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>0.5 mL of phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Immediate Adverse Events</title>
          <description>Any adverse event occurring within the 30 minute post vaccination period.</description>
          <population>The analysis was conducted for subjects who were randomized and received a study vaccination.</population>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number and Percentage of Participants Reporting Solicited Local Reactogenicity</title>
        <description>Number of subjects reporting solicited local reactions (redness, swelling, pain, hardness, and tenderness) at the injection site post-vaccination with study vaccine or placebo.</description>
        <time_frame>7-day period (Days 1-7) post-vaccination.</time_frame>
        <population>The analysis was conducted for subjects who were randomized and received a study vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Group</title>
            <description>0.5 mL of seasonal trivalent influenza vaccine with 15 mcg of HA of each of 3 strains: B, H1N1, &amp; H3N2</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>0.5 mL of phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Participants Reporting Solicited Local Reactogenicity</title>
          <description>Number of subjects reporting solicited local reactions (redness, swelling, pain, hardness, and tenderness) at the injection site post-vaccination with study vaccine or placebo.</description>
          <population>The analysis was conducted for subjects who were randomized and received a study vaccination</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hardness</title>
              <category_list>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity</title>
        <description>Number of subjects reporting solicted systemic reactions (fever, fatigue/malaise, muscle aches, joint aches, chills, nausea, vomiting, and headache) post-vaccination with study vaccine or placebo</description>
        <time_frame>7-day period (Days 1-7) post-vaccination</time_frame>
        <population>The analysis was conducted for subjects who were randomized and received a study vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Group</title>
            <description>0.5 mL of seasonal trivalent influenza vaccine with 15 mcg of each of 3 strains: B, H1N1, &amp; H3N2</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>0.5 mL of phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity</title>
          <description>Number of subjects reporting solicted systemic reactions (fever, fatigue/malaise, muscle aches, joint aches, chills, nausea, vomiting, and headache) post-vaccination with study vaccine or placebo</description>
          <population>The analysis was conducted for subjects who were randomized and received a study vaccination</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tiredness/discomfort</title>
              <category_list>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle aches</title>
              <category_list>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint aches</title>
              <category_list>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number and Percentage of Participants With Unsolicited Adverse Events</title>
        <description>Unsolicited AEs were any AEs that occurred any time after the vaccine/placebo was administered (temporally related to investigational product), whether or not deemed &quot;related&quot; to the product, and are not solicited (specifically asked of the subject). Unsolicited AEs were to be observed by the study center personnel while the subject was at the study center for a study visit or reported by the subject at any time. Any sign or symptom that would normally be considered a &quot;solicited AE&quot; (for example, fever, nausea, injection site pain) starting after 7 days post-vaccination were to be recorded as an &quot;unsolicited AE. In this study, laboratory results were considered AEs when (1) the result was judged to be clinically significant by the Principal Investigator, regardless of grade; or (2) the result is Grade 2 or higher.
Note: all unsolicited AEs were mild in intensity. Please see Adverse Events section of this report for detailed information of AEs.</description>
        <time_frame>Within 21 days post-vaccination</time_frame>
        <population>The analysis was conducted for subjects who were randomized and received a study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Group</title>
            <description>0.5 mL of seasonal influenza vaccine with 15 mcg of HA of each of 3 strains: B, H1N1, &amp; H3N2</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>0.5 mL of phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Participants With Unsolicited Adverse Events</title>
          <description>Unsolicited AEs were any AEs that occurred any time after the vaccine/placebo was administered (temporally related to investigational product), whether or not deemed &quot;related&quot; to the product, and are not solicited (specifically asked of the subject). Unsolicited AEs were to be observed by the study center personnel while the subject was at the study center for a study visit or reported by the subject at any time. Any sign or symptom that would normally be considered a &quot;solicited AE&quot; (for example, fever, nausea, injection site pain) starting after 7 days post-vaccination were to be recorded as an &quot;unsolicited AE. In this study, laboratory results were considered AEs when (1) the result was judged to be clinically significant by the Principal Investigator, regardless of grade; or (2) the result is Grade 2 or higher.
Note: all unsolicited AEs were mild in intensity. Please see Adverse Events section of this report for detailed information of AEs.</description>
          <population>The analysis was conducted for subjects who were randomized and received a study vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number and Percentage of Participants With Serious Adverse Events (SAEs)</title>
        <time_frame>Over the entire study period (Day 91)</time_frame>
        <population>The analysis was conducted for subjects who were randomized and received a study vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Group</title>
            <description>0.5 mL of influenza vaccine split, inactivated with 15 mcg of HA of each of 3 strains: B, H1N1, &amp; H3N2</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>0.5 mL of phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Participants With Serious Adverse Events (SAEs)</title>
          <population>The analysis was conducted for subjects who were randomized and received a study vaccination</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events (SAEs)--related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs--not related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Subjects With Seroconversion Against Each of the 3 Antigens</title>
        <description>Seroconversion is defined as a serum HAI titer meeting the following criteria:
pre-vaccination titer &lt;1:10 and a post-vaccination titer ≥ 1:40 or
pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination measured on Day 22.</description>
        <time_frame>Day 22</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Group</title>
            <description>0.5 mL of seasonal trivalent influenza vaccine with 15 mcg of HA of each of 3 strains: B, H1N1, &amp; H3N2</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>0.5 mL of Phosphate Buffered Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects With Seroconversion Against Each of the 3 Antigens</title>
          <description>Seroconversion is defined as a serum HAI titer meeting the following criteria:
pre-vaccination titer &lt;1:10 and a post-vaccination titer ≥ 1:40 or
pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination measured on Day 22.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seroconversion rate to H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion rate to H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion rate to B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Seroprotected Subjects Against 3 Strains of Influenza Vaccine</title>
        <description>A seroprotected subject was defined as a vaccinated subject who had a serum Hemagluttination Inhibition (HAI) titer &gt;/= 1:40. The 3 influenza strains assessed were B, H1, and H3.</description>
        <time_frame>Day 1 and Day 22 post vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Group</title>
            <description>0.5 mL of influenza vaccine split, inactivated with 15 mcg of HA of each of 3 strains: B, H1N1, &amp; H3N2</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>0.5 mL of phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Seroprotected Subjects Against 3 Strains of Influenza Vaccine</title>
          <description>A seroprotected subject was defined as a vaccinated subject who had a serum Hemagluttination Inhibition (HAI) titer &gt;/= 1:40. The 3 influenza strains assessed were B, H1, and H3.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) of Serum Hemaggluntination Inhibition (HAI) Antibodies for Each Antigen</title>
        <description>Geometric mean titers (GMTs) of Serum Hemaggluntination Inhibition (HAI) antibodies pre- (Day 1) and post-vaccination (Day 22) for each of the 3 antigens.</description>
        <time_frame>Pre- (Day 1) and post-vaccination (Day 22)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Trivalent Seasonal Influenza Vaccine</title>
            <description>0.5 mL of seasonal trivalent influenza vaccine with 15 mcg of HA of each of 3 strains: B, H1N1, &amp; H3N2</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.5 mL of Phosphate Buffered Saline
Placebo Comparator: Placebo (PBS)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) of Serum Hemaggluntination Inhibition (HAI) Antibodies for Each Antigen</title>
          <description>Geometric mean titers (GMTs) of Serum Hemaggluntination Inhibition (HAI) antibodies pre- (Day 1) and post-vaccination (Day 22) for each of the 3 antigens.</description>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMT to H1 Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="6.7" upper_limit="15.0"/>
                    <measurement group_id="O2" value="10.6" lower_limit="7.1" upper_limit="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT to H1 Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="371.9" lower_limit="245.4" upper_limit="563.6"/>
                    <measurement group_id="O2" value="10.7" lower_limit="7.2" upper_limit="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT to H3 Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.5" lower_limit="22.9" upper_limit="68.4"/>
                    <measurement group_id="O2" value="35.6" lower_limit="21.8" upper_limit="58.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT to H3 Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="640" lower_limit="419.2" upper_limit="977.1"/>
                    <measurement group_id="O2" value="33.6" lower_limit="21.6" upper_limit="52.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT to B Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" lower_limit="6.7" upper_limit="11.6"/>
                    <measurement group_id="O2" value="6.9" lower_limit="5.8" upper_limit="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT to B Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.1" lower_limit="47.1" upper_limit="98.2"/>
                    <measurement group_id="O2" value="7.0" lower_limit="5.9" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rises (GMFRs) of Serum Hemaggluntination Inhibition (HAI) Antibodies</title>
        <description>Geometric mean fold rises (GMFRs) of serum hemaggluntination inhibition (HAI) antibodies post-vaccination/pre-vaccination for each of the 3 antigens</description>
        <time_frame>Day 22/Day1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Trivalent Seasonal Influenza Vaccine</title>
            <description>0.5 mL of seasonal trivalent influenza vaccine with 15 mcg of HA of each of 3 strains: B, H1N1, &amp; H3N2</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.5 mL of Phosphate Buffered Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rises (GMFRs) of Serum Hemaggluntination Inhibition (HAI) Antibodies</title>
          <description>Geometric mean fold rises (GMFRs) of serum hemaggluntination inhibition (HAI) antibodies post-vaccination/pre-vaccination for each of the 3 antigens</description>
          <units>fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMFR Day 22/Day 1 for H1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.2" lower_limit="23.7" upper_limit="58.3"/>
                    <measurement group_id="O2" value="1" lower_limit="0.9" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMFR Day 22/Day 1 for H3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" lower_limit="9.2" upper_limit="28.4"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.9" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMFR Day 22/Day 1 for B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="5.0" upper_limit="12.1"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.9" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Neutralization Titers of Neutralizing Antibodies (MNT) Pre- (Day 1) and Post-Vaccination (Day 22) for Each of the 3 Antigens</title>
        <time_frame>Pre- (Day 1) and Post-vaccination (Day 22)</time_frame>
        <population>All vaccinated subjects who have valid post vaccination immunogenicity measures with no major protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Group</title>
            <description>0.5 mL of influenza vaccine split, inactivated with 15 mcg of HA of each of 3 strains: B, H1N1, &amp; H3N2</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>0.5 mL of phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Neutralization Titers of Neutralizing Antibodies (MNT) Pre- (Day 1) and Post-Vaccination (Day 22) for Each of the 3 Antigens</title>
          <population>All vaccinated subjects who have valid post vaccination immunogenicity measures with no major protocol deviations</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMT to H1 Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="6.0" upper_limit="12.5"/>
                    <measurement group_id="O2" value="10.8" lower_limit="7.3" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT to H1 Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="417.4" lower_limit="263.0" upper_limit="662.4"/>
                    <measurement group_id="O2" value="10.5" lower_limit="7.2" upper_limit="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT to H3 Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.6" lower_limit="22.4" upper_limit="63.8"/>
                    <measurement group_id="O2" value="40.0" lower_limit="23.5" upper_limit="68.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT to H3 Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="670.3" lower_limit="405.9" upper_limit="1106.7"/>
                    <measurement group_id="O2" value="39.1" lower_limit="23.1" upper_limit="66.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT to B Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" lower_limit="10.3" upper_limit="25.6"/>
                    <measurement group_id="O2" value="14.6" lower_limit="10.4" upper_limit="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT to B Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201.6" lower_limit="123.6" upper_limit="328.8"/>
                    <measurement group_id="O2" value="14.3" lower_limit="10.2" upper_limit="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Fold Rises (GMFRs) of Neutralizing Antibodies (MNT) Post-vaccination/Pre-vaccination for Each of the 3 Antigens</title>
        <time_frame>Pre- (Day 1) and Post-vaccination (Day 22)</time_frame>
        <population>All vaccinated subjects who have valid post-vaccination immunogenicity measures with no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Group</title>
            <description>0.5 mL of influenza vaccine split, inactivated with 15 mcg of HA of each of 3 strains: B, H1N1, &amp; H3N2</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>0.5 mL of phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Fold Rises (GMFRs) of Neutralizing Antibodies (MNT) Post-vaccination/Pre-vaccination for Each of the 3 Antigens</title>
          <population>All vaccinated subjects who have valid post-vaccination immunogenicity measures with no major protocol violations</population>
          <units>fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMFR for H1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.9" lower_limit="29.1" upper_limit="79.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.9" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMFR for B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" lower_limit="6.9" upper_limit="22.3"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.9" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMFR for H3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="9.7" upper_limit="31.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.9" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90 days</time_frame>
      <desc>We included AEs that occurred any time after the vaccine/placebo was administered , whether or not deemed “related” to the product, and are not solicited (specifically asked of the subject) unless they started after 7 days post-vaccination. In this study, laboratory results were considered AEs when (1) the result was judged to be clinically significant by the Principal Investigator, regardless of grade; or (2) the result is Grade 2 or higher.
Note: all unsolicited AEs were mild in intensity.</desc>
      <group_list>
        <group group_id="E1">
          <title>Trivalent Seasonal Influenza Vaccine</title>
          <description>0.5 mL of seasonal trivalent influenza vaccine with 15 mcg of HA of each of 3 strains: B, H1N1, &amp; H3N2</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>0.5 mL of Phosphate Buffered Saline</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain/sore throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Le Van Be</name_or_title>
      <organization>IVAC</organization>
      <email>ivaclevanbe@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

